J. B. Chemicals & Pharmaceuticals Limited

NSEI:JBCHEPHARM Stock Report

Market Cap: ₹271.5b

J. B. Chemicals & Pharmaceuticals Valuation

Is JBCHEPHARM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of JBCHEPHARM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: JBCHEPHARM (₹1749.7) is trading above our estimate of fair value (₹561.4)

Significantly Below Fair Value: JBCHEPHARM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JBCHEPHARM?

Key metric: As JBCHEPHARM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for JBCHEPHARM. This is calculated by dividing JBCHEPHARM's market cap by their current earnings.
What is JBCHEPHARM's PE Ratio?
PE Ratio44.4x
Earnings₹6.11b
Market Cap₹271.45b

Price to Earnings Ratio vs Peers

How does JBCHEPHARM's PE Ratio compare to its peers?

The above table shows the PE ratio for JBCHEPHARM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.2x
GLAND Gland Pharma
41.5x25.8%₹286.8b
AJANTPHARM Ajanta Pharma
42.8x16.4%₹374.3b
IPCALAB Ipca Laboratories
60.1x29.9%₹397.3b
524558 Neuland Laboratories
68.6x33.9%₹191.7b
JBCHEPHARM J. B. Chemicals & Pharmaceuticals
44.4x19.4%₹271.5b

Price-To-Earnings vs Peers: JBCHEPHARM is good value based on its Price-To-Earnings Ratio (44.4x) compared to the peer average (53.2x).

Price to Earnings Ratio vs Industry

How does JBCHEPHARM's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.5xn/aUS$67.74m
524652 Ind-Swift
2xn/aUS$13.11m
No more companies available in this PE range
JBCHEPHARM 44.4xIndustry Avg. 34.2xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: JBCHEPHARM is expensive based on its Price-To-Earnings Ratio (44.4x) compared to the Indian Pharmaceuticals industry average (34.2x).

Price to Earnings Ratio vs Fair Ratio

What is JBCHEPHARM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JBCHEPHARM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio44.4x
Fair PE Ratio41.8x

Price-To-Earnings vs Fair Ratio: JBCHEPHARM is expensive based on its Price-To-Earnings Ratio (44.4x) compared to the estimated Fair Price-To-Earnings Ratio (41.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst JBCHEPHARM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,749.70
₹2,173.77
+24.2%
8.4%₹2,330.00₹1,686.00n/a13
Nov ’25₹1,960.30
₹2,118.00
+8.0%
8.5%₹2,343.00₹1,651.00n/a13
Oct ’25₹1,834.95
₹2,105.69
+14.8%
8.1%₹2,255.00₹1,651.00n/a13
Sep ’25₹1,953.80
₹2,086.17
+6.8%
8.1%₹2,230.00₹1,651.00n/a12
Aug ’25₹1,912.55
₹1,975.42
+3.3%
7.3%₹2,200.00₹1,631.00n/a12
Jul ’25₹1,792.80
₹1,975.42
+10.2%
7.3%₹2,200.00₹1,631.00n/a12
Jun ’25₹1,771.90
₹1,929.83
+8.9%
10.1%₹2,200.00₹1,519.00n/a12
May ’25₹1,905.25
₹1,881.73
-1.2%
10.1%₹2,200.00₹1,500.00n/a11
Apr ’25₹1,695.55
₹1,886.70
+11.3%
10.9%₹2,200.00₹1,500.00n/a10
Mar ’25₹1,531.40
₹1,886.70
+23.2%
10.9%₹2,200.00₹1,500.00n/a10
Feb ’25₹1,685.35
₹1,746.80
+3.6%
8.3%₹1,970.00₹1,471.00n/a10
Jan ’25₹1,615.60
₹1,689.80
+4.6%
8.0%₹1,860.00₹1,367.00n/a10
Dec ’24₹1,460.45
₹1,566.32
+7.2%
11.4%₹1,775.00₹1,137.50n/a11
Nov ’24₹1,400.15
₹1,465.27
+4.7%
10.9%₹1,657.00₹1,137.50₹1,960.3011
Oct ’24₹1,482.10
₹1,465.23
-1.1%
10.9%₹1,657.00₹1,137.50₹1,834.9511
Sep ’24₹1,398.08
₹1,422.05
+1.7%
12.3%₹1,657.00₹1,137.50₹1,953.8011
Aug ’24₹1,287.68
₹1,181.75
-8.2%
8.0%₹1,340.00₹951.50₹1,912.5512
Jul ’24₹1,183.48
₹1,179.25
-0.4%
7.9%₹1,340.00₹951.50₹1,792.8012
Jun ’24₹1,058.38
₹1,164.64
+10.0%
7.2%₹1,268.00₹951.50₹1,771.9011
May ’24₹1,064.93
₹1,138.40
+6.9%
6.0%₹1,237.50₹1,040.00₹1,905.2510
Apr ’24₹988.18
₹1,137.40
+15.1%
6.1%₹1,237.50₹1,030.00₹1,695.5510
Mar ’24₹995.93
₹1,137.40
+14.2%
6.1%₹1,237.50₹1,030.00₹1,531.4010
Feb ’24₹1,010.40
₹1,140.55
+12.9%
4.8%₹1,230.00₹1,050.00₹1,685.3510
Jan ’24₹972.25
₹1,140.55
+17.3%
4.8%₹1,230.00₹1,050.00₹1,615.6010
Dec ’23₹1,009.00
₹1,146.19
+13.6%
4.7%₹1,230.00₹1,050.00₹1,460.458
Nov ’23₹999.50
₹1,064.19
+6.5%
7.6%₹1,194.50₹965.00₹1,400.158

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,196.05

7D

0.8%

1Y

-22.8%

Colinz Laboratories

₹141.3m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹56.10

7D

3.0%

1Y

37.2%